Suppression of anti-tumor immunity was reversed by the addition of anti-TGF-β antibody or COX-2 inhibitor, supporting the rationale for inhibition of TGF-β and COX-2 pathways to overcome potential immunosuppressive effects due to EGFR inhibition. The gene discussed is TGFB1; the disease is neoplasm.